Evidence map›Paper›PMID 28176171›Full record

ArticleInternational ophthalmology2018

Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema.

Yen-Yi Chen, Pei-Ying Chen, Fang-Ting Chen, Yun-Ju Chen, Jia-Kang Wang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yen-Yi ChenDepartment of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan.
Pei-Ying ChenDepartment of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan.
Fang-Ting ChenDepartment of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan.
Yun-Ju ChenDepartment of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan.
Jia-Kang WangDepartment of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan. jiakangw2158@gmail.com.
National Yang Ming Chiao Tung University · TWFar Eastern Memorial Hospital · TW

Funding

Far Eastern Memorial Hospital FEMH - 2016-C-044
6 · The paper itself

Abstract

purposeTo compare the efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema (DME). STUDY

designA retrospective, nonrandomized, and comparative study.

methodsFrom May 2013 to March 2016, 148 eyes of 148 patients with treatment-naïve center-involving DME were reviewed in one institution. Forty-six eyes underwent prior vitrectomy at least 3 months ago, and 102 eyes did not receive any vitrectomy. Three monthly then PRN intravitreal ranibizumab treatments were performed in all the patients with monthly follow-up for 6 months. Primary outcome measures included change in central foveal thickness (CFT) and best-corrected visual acuity (BCVA) at month 6.

resultsThe CFT significantly reduced, and the BCVA significantly improved 6 months after ranibizumab injections in either vitrectomized or non-vitrectomized groups (p < 0.05). There was no difference between vitrectomized and non-vitrectomized eyes in baseline characteristics. Significantly better final BCVA and visual gain were found in non-vitrectomized eyes than in vitrectomized eyes (p = 0.01 and 0.03, respectively). Final CFT and CFT decrease were significantly greater in non-vitrectomized group than in vitrectomized group (p = 0.02 and 0.006, respectively). Injection number of ranibizumab was 4.12 ± 0.58 in non-vitrectomized eyes, significantly less than that in vitrectomized eyes (5.05 ± 0.71) during 6-month period (p < 0.001). There were no severe systemic/ocular adverse effects in both groups.

conclusionsIntravitreal ranibizumab was helpful for either vitrectomized or non-vitrectomized eyes with DME in short-term follow-up. Anatomical and functional improvements were greater in non-vitrectomized patients than in vitrectomized cases.

Indexed as

Diabetes MellitusVitrectomyAngiogenesis InhibitorsDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIntravitreal InjectionsMacula LuteaMacular EdemaMaleMiddle AgedRanibizumabRetrospective StudiesTime FactorsTomography, Optical CoherenceAngiogenesis InhibitorsRanibizumabDiabetic macular edemaIntravitreal injectionRanibizumabVitrectomized eyes

Identifiers

PMID28176171
OpenAlexW2586699007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.